ReviewSignal transduction and targeted therapy2026
Advancing high-altitude medicine: a model for the future.
Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With rising global high-altitude travel, occupational exposure, and permanent habitation, the health burden of high-altitude-specific diseases and high-altitude-related diseases has become increasingly prominent, highlighting an urgent need for in-depth research and clinical solutions in high-altitude medicine. To bridge this gap, this prospective review first proposes the Hypoxia Stress-induced Multi-organ Injury (HSMI) Spectrum as a novel, unifying research paradigm-one that seeks to overcome the limitations of fragmented traditional research by integrating insights into hypoxia-driven multi-organ pathophysiology. Despite growing foundational advances, critical barriers remain: incomplete understanding of individual hypoxia susceptibility mechanisms, overreliance on subjective and non-mechanism-based diagnostic tools, and a profound translational chasm between basic research and clinical therapeutics, especially for vulnerable groups like neonates, the elderly, and females. Building on the HSMI framework, we outline a comprehensive advancement strategy that includes establishing an integrated systems-based research model leveraging multi-omics and machine learning, deciphering core hypoxia-driven molecular pathways, developing objective real-time diagnostic systems with biomarkers and portable imaging, and innovating mechanism-based precision therapeutics. Implementing this HSMI-centered model will strengthen the scientific foundation of high-altitude medicine, optimize the prevention, diagnosis, and treatment of high-altitude illnesses, and offer a scalable framework for addressing health challenges in extreme hypoxic environments worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.